Comparison between visual assessment of dopaminergic degeneration pattern and semi-quantitative ratio calculations in patients with Parkinson’s disease and Atypical Parkinsonian syndromes using DaTSCAN® SPECT

ObjectiveTo verify if 123I-FP-CIT, DaTSCAN® can differentiate early stages of Parkinson’s disease (PD) as well as patients with Atypical Parkinsonian syndromes (APS) from manifest Parkinson’s disease.Methods128 consecutive patients were investigated with 123I-FP-CIT SPECT during a 4-year period. All patients were diagnosed according to the established consensus criteria for diagnosis of PD (n = 53) and APS (n = 19). Remaining patients were grouped early PD (before onset of l-DOPA medication), (n = 20), vascular PD (n = 6), and non-PD syndromes (n = 30) and SWEDD (n = 1). SPECT images were analyzed visually according to a predefined ranking scale of dopaminergic nerve cell degeneration, distinguishing a posterior–anterior degeneration pattern (egg shape) from a more global and severe degeneration pattern (burst striatum). Striatum uptake ratios were quantitatively analyzed with the 3D software, EXINI.ResultsIn the group of APS patients, the burst striatum pattern was most frequent and found in 61 % (11/18 patients). In PD patients, the egg shape pattern was dominating, especially in early PD where it was present in 95 % (19/20 patients). The positive predictive value for the egg shape pattern to diagnose PD was 92 % in this material (APS and all PD patients) and the specificity 90 % for the burst striatum pattern to exclude APS. The uptake ratios were reduced in both PD and APS patients and closely related to the image ranking.ConclusionIn this study, we found that in more than half of the patients it was possible to differentiate between PD and APS by visual interpretation only. Similar results were obtained using semi-quantitative uptake ratios. Combining visual assessment with uptake ratios did not add to the discriminating power of DaTSCAN® SPECT in this material.

[1]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[2]  A. Antonini,et al.  EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease , 2013, European journal of neurology.

[3]  L. Timmermann,et al.  Visual assessment of dopaminergic degeneration pattern in 123I-FP-CIT SPECT differentiates patients with atypical parkinsonian syndromes and idiopathic Parkinson's disease , 2012, Journal of Neurology.

[4]  S. Asenbaum,et al.  SPECT and PET imaging of the dopaminergic system in Parkinson's disease , 2000, Journal of Neurology.

[5]  W. Meissner,et al.  Multiple system atrophy: current and future approaches to management , 2010, Therapeutic advances in neurological disorders.

[6]  M. McKeown,et al.  Invited Article: Functional imaging in Parkinson disease , 2008, Neurology.

[7]  M. Breteler,et al.  Epidemiology of Parkinson's disease , 2006, The Lancet Neurology.

[8]  Robert B. Innis,et al.  [123I]β‐CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy , 2001 .

[9]  Jan Booij,et al.  SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. , 2007, Parkinsonism & related disorders.

[10]  John Seibyl,et al.  SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* , 2012, The Journal of Nuclear Medicine.

[11]  Xanthi Pedeli,et al.  Interobserver variability, and visual and quantitative parameters of 123I-FP-CIT SPECT (DaTSCAN) studies , 2012, Annals of Nuclear Medicine.

[12]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[13]  I. McKeith,et al.  SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders , 2003, Movement disorders : official journal of the Movement Disorder Society.

[14]  K. Jellinger Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? , 1999, Journal of neural transmission. Supplementum.

[15]  Dae Hyuk Moon,et al.  Subregional Patterns of Preferential Striatal Dopamine Transporter Loss Differ in Parkinson Disease, Progressive Supranuclear Palsy, and Multiple-System Atrophy , 2012, The Journal of Nuclear Medicine.

[16]  Koen Van Laere,et al.  EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2 , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  V. Sossi,et al.  In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease , 2000, Annals of neurology.

[18]  B. Långström,et al.  Regulation of dopaminergic activity in early Parkinson's disease , 1999, Annals of neurology.

[19]  A. Jon Stoessl,et al.  Neuroimaging in Parkinson’s Disease , 2011, Neurotherapeutics.

[20]  L. Wojtecki,et al.  Diagnostic Accuracy of Combined FP-CIT, IBZM, and MIBG Scintigraphy in the Differential Diagnosis of Degenerative Parkinsonism: A Multidimensional Statistical Approach , 2011, The Journal of Nuclear Medicine.

[21]  F. Zhang,et al.  Resveratrol Protects Dopamine Neurons Against Lipopolysaccharide-Induced Neurotoxicity through Its Anti-Inflammatory Actions , 2010, Molecular Pharmacology.

[22]  J. Seibyl,et al.  [(123)I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. , 2001, Movement disorders : official journal of the Movement Disorder Society.

[23]  H. Berendse,et al.  Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. , 2009, Parkinsonism & related disorders.

[24]  R. Nagele,et al.  Diagnosis of Parkinson's Disease Based on Disease-Specific Autoantibody Profiles in Human Sera , 2011, PloS one.

[25]  W. Poewe,et al.  Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial , 2013, The Lancet Neurology.

[26]  M. Savoiardo Differential diagnosis of Parkinson's disease and atypical parkinsonian disorders by magnetic resonance imaging , 2003, Neurological Sciences.

[27]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[28]  Donald Grosset,et al.  Role of dopamine transporter imaging in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.

[29]  R J Jaszczak,et al.  Whole-body single-photon emission computed tomography using dual, large-field-of-view scintillation cameras , 1979, Physics in medicine and biology.

[30]  Andrew J Lees,et al.  Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis , 2004, Movement disorders : official journal of the Movement Disorder Society.

[31]  K. Riklund,et al.  Pre- and postsynaptic dopamine SPECT in the early phase of idiopathic parkinsonism: a population-based study , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  Masanori Ichise,et al.  Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP , 2002, Movement disorders : official journal of the Movement Disorder Society.

[33]  C. Blomstrand,et al.  Functional assessment of high-grade ICA stenosis with duplex ultrasound and transcranial Doppler , 2012, Clinical physiology and functional imaging.